Cam­bridge spin­out Cell­Cen­tric gets $26M for sin­gle-as­set epi­ge­net­ics ap­proach to prostate can­cer

Can a biotech de­vel­op­ing an epi­ge­net­ics drug squeeze in­to J&J and Pfiz­er’s turf fight in prostate can­cer? Cam­bridge, UK-based Cell­Cen­tric now has $26 mil­lion to find out.

Morn­ing­side Ven­ture In­vest­ments pro­vid­ed all of the fund­ing, con­tin­u­ing to throw its weight be­hind UK-based Cell­Cen­tric’s lead and on­ly as­set, CCS1477. The mon­ey is ex­pect­ed to car­ry the p300/CBP in­hibitor through Phase IIb in prostate can­cer and al­low the small vir­tu­al team to es­tab­lish sep­a­rate pro­grams in hema­to­log­i­cal or oth­er can­cers.

“The idea is to stay very as­set cen­tric, very fo­cused on one pro­gram, but look for mul­ti­ple op­por­tu­ni­ties now to use it,” CEO Will West tells me.

Ja­son Dinges

And he’s con­fi­dent CCS1477 is the as­set to cen­ter around. As re­cent­ly as five years ago, Cell­Cen­tric was a “knowl­edge com­pa­ny” that helped oth­er com­pa­nies ex­plore epi­ge­net­ic path­ways and cel­lu­lar re­pro­gram­ming. When it tran­si­tioned in­to an R&D op­er­a­tion in 2013 — thanks to ma­jor sup­port from Morn­ing­side — the team hand picked p300/CBP out of 50 po­ten­tial epi­ge­net­ic-re­lat­ed drug tar­gets.

Giv­en the role of hor­mones in fu­el­ing prostate can­cer cell growth, an­dro­gen re­cep­tors are a pop­u­lar tar­get for drug de­vel­op­ers — but even sec­ond gen­er­a­tion an­ti-an­dro­gen treat­ments have proven sus­cep­ti­ble to re­sis­tance. Down­reg­u­lat­ing the twin tar­gets of p300/CBP, West ex­plains, dri­ves down not on­ly an­dro­gen re­cep­tors but al­so all its vari­ants. That po­si­tions them as a fol­low up, com­pan­ion, or even pos­si­ble re­place­ment for block­busters like J&J’s Zyti­go and Er­lea­da as well as Pfiz­er/Astel­las’ Xtan­di.

“For the prostate in­di­ca­tion, it’s very clear and clean what we’re try­ing to do,” West says.

While Cell­Cen­tric’s drug be­longs to the BET in­hibitor fam­i­ly, it’s dis­tinct in both its speci­fici­ty and (based up­on pre­clin­i­cal stud­ies) du­ra­tion of ef­fect — al­low­ing for flex­i­bil­i­ty in dos­ing sched­ule, which is “ab­solute­ly key.” That means while the cur­rent plan is for pa­tients to take the oral cap­sule once a day, they could switch to an in­ter­mit­tent sched­ule or a “three week on, one week off hol­i­day ap­proach” if nec­es­sary.

The prostate can­cer clin­i­cal pro­gram is slat­ed to be­gin this sum­mer. By the end of the year West hopes to have a hema­to­log­i­cal can­cer pro­gram run­ning, with par­tic­u­lar fo­cus on acute myeloid leukemia and mul­ti­ple myelo­ma. Look­ing down the road, he al­so sees the drug treat­ing sub-pop­u­la­tions of blad­der can­cer and small cell lung can­cer pa­tients.

West has four col­leagues spread be­tween Cam­bridge, Ox­ford and Man­ches­ter to man­age 10 times as many con­sul­tants work­ing on the drug. And he doesn’t see the core team chang­ing much — un­less a big­ger play­er comes in to snap them up.

For now, New­ton, MA-based Morn­ing­side con­tin­ues to be Cell­Cen­tric’s largest share­hold­er, fol­lowed by Prov­i­dence In­vest­ment Com­pa­ny.

“On­col­o­gy prod­uct de­vel­op­ment is high­ly com­pet­i­tive. There are few gen­uine first-in-class new drug op­por­tu­ni­ties which have a large but spe­cif­ic pa­tient pop­u­la­tion to treat,” said Morn­ing­side’s Ja­son Dinges, who’s al­so on Cell­Cen­tric’s board. “We are de­light­ed to sup­port the Cell­Cen­tric team with their con­tin­ued mo­men­tum.”

Mi­no­ryx and Sper­o­genix ink an ex­clu­sive li­cense agree­ment to de­vel­op and com­mer­cial­ize lerigli­ta­zone in Chi­na

September 23, 2020 – Hong Kong, Beijing, Shanghai (China) and Mataró, Barcelona (Spain)  

Minoryx will receive an upfront and milestone payments of up to $78 million, as well as double digit royalties on annual net sales 

Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition

President Trump walks past HHS secretary Alex Azar (Getty Images)

Azar falls in line un­der Trump again. Ex­perts say he's re­in­forc­ing a dark sig­nal sent to the FDA

In the latest incident where Alex Azar has steadfastly taken the side of President Donald Trump over that of the FDA, the HHS secretary was noncommittal this morning when asked if he supports the attempt by his subordinates at the FDA to strengthen guidelines for a vaccine EUA.

Appearing on NBC’s Today Show, the HHS secretary muddied the waters, stating that the guidance that matters is the one that is “actually already out there.”

CDC’s Robert Redfield, NIAID’s Anthony Fauci, Admiral Brett Giroir at HHS, and FDA’s Stephen Hahn prepare to testify at a House hearing on June 23 (Getty)

'Ex­treme­ly po­lit­i­cal' — Trump neuters FDA's at­tempt to strength­en vac­cine EUA

Stephen Hahn went before a Senate committee Wednesday and declared he’s fighting. “Every one of the decisions we have reached has been made by career FDA scientists based on science and data, not politics,” he exclaimed, adding that “FDA will not permit any pressure from anyone to change that. I will fight for science.”

A few hours later, he was undermined by President Donald Trump when a reporter asked if he was okay with stricter vaccine guidelines that the FDA was said to be cooking up. “That has to be approved by the White House. We may or may not approve it. That sounds like a political move,” he decided.

David Berry (Flagship)

Flag­ship's next big tech­no­log­i­cal bet? The cloud

Earlier this month, Flagship announced their big bet on the software half the industry is talking about, launching the AI and machine learning startup. Now, they and a couple other investors are gambling $100 million on a software that much of the public generally thinks of as a cool, IT afterthought: cloud computing.

The idea, says founder and Flagship partner David Berry, is one of scale: The sheer magnitude of biological data that you can store on cloud technology is unprecedented. And that size, when leveraged properly, can allow you to ask questions and form insights that are similarly unprecedented.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.

New York governor Andrew Cuomo (AP Images)

An­drew Cuo­mo says New York will un­der­take its own vac­cine re­view process, and wouldn’t rec­om­mend trust­ing the fed­er­al gov­ern­ment

The concerns keep mounting over President Donald Trump’s politicization of the FDA and other federal agencies guiding the development of a safe and effective vaccine. And today, the telegenic New York governor Andrew Cuomo appeared to introduce even more politics into the matter — latest in an ongoing series of incidents that have cast the proudly independent FDA in starkly political terms.

During his daily press conference Cuomo said that the state will review any coronavirus vaccines approved by the federal government, citing a lack of trust of the Trump administration. The announcement comes one day after Trump accused the FDA of making an “extremely political” move in proposing stricter vaccine guidance.

Patrick Enright, Longitude co-founder (Longitude)

As its biotechs hit the pan­dem­ic ex­it, Lon­gi­tude rais­es $585M for new neu­ro, can­cer, ag­ing and or­phan-fo­cused fund

The years have been kind to Longitude Capital. This year, too.

A 2006 spinout of Pequot Capital, its founders started their new firm just four years before the parent company would go under amid insider trading allegations. Their first life sciences fund raised $325 million amid the financial crisis, they added a second for $385 million and then in, 2016, a third for $525 million. In the last few months, the pandemic biotech IPO boom netted several high-value exits from those funds, as Checkmate, Vaxcyte, Inozyme and Poseida all went public.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.

Laura Shawver (Silverback Therapeutics)

Fol­low­ing a hefty Se­ries B, Sil­ver­back Ther­a­peu­tics quick­ly pulls in $85M for 'an im­por­tant growth phase'

Months after reeling in a $78 million Series B round, Silverback Therapeutics has hooked an even larger Series C.

The Seattle-based company announced Wednesday that it netted $85 million from a slate of new and previous investors. The quick boost could be a sign that an IPO is on the way.

In an email, Silverback CEO Laura Shawver told me she was “not able to provide any additional comments about Silverback” beyond what was shared in the company’s news release. In the prepared statement, she said the company is at “an important growth phase.”

Covid-19 roundup: Op­er­a­tion Warp Speed's 7th vac­cine is live at­ten­u­at­ed; Small biotech touts big suc­cess where gi­ants have failed

Operation Warp Speed is stacking its vaccine portfolio with a “TBD” new candidate: a live attenuated vaccine that can be administered in a single dose, potentially as an oral formulation rather than an injection.

Sound familiar?

That could be because the unannounced candidate appears to match the profile of an inoculation being developed by Merck, according to Bloomberg, which first reported the development based on a presentation by Moncef Slaoui.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.

On­ly five months af­ter a Se­ries A launch, Taysha goes pub­lic with $157M IPO

As has been the trend in 2020, Taysha Gene Therapies has become the latest biotech to make a quick ascent from a small, privately-funded company to enjoying its very own Nasdaq ticker.

The Dallas-based biotech raised $157 million for its IPO after pricing shares at $20 apiece Thursday, the high-point of its expected range. Initially pegging $100 million in financing, Taysha offered a little less than 8 million shares and will trade under the $TSHA symbol.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.